Author

E. Kulesskiy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Organism:C. elegans· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. Ianevski· 2 shared D. E. Kainov· 2 shared E. Zusinaite· 2 shared H. Lysvand· 2 shared M. Bjoras· 2 shared V. Oksenych· 2 shared A. Bugai· 1 shared A. F. Arutyunyan· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Ianevski

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Identification of novel antiviral drug combinations in vitro and tracking their development

A. Ianevski, R. Yao, S. Biza, E. Zusinaite, A. Mannik, G. Kivi, A. Planken, K. Kurg, E.-M. Tombak, M. Ustav, N. Shtaida, E. Kulesskiy, E. Jo, J. Yang, H. Lysvand, , D. E. Kainov

This study identifies novel synergistic antiviral drug combinations effective against SARS-CoV-2, echovirus 1, HCV, and HIV-1 in vitro and provides an online resource for their developmental status.

bioRxiv · Sep 17, 2020 · PreprintMicrobiology

Chemical, physical and biological triggers of Bcl-xL-mediated apoptosis

A. Ianevski, E. Kulesskiy, K. Krpina, G. Lou, Y. Aman, A. Bugai, K. Aasumets, Y. Akimov, D. Bulanova, K. Gildemann, A. F. Arutyunyan, O. Y. Susova, A. L. Zhuze, P. Ji, W. Wang, , D. E. Kainov

This study shows that Bcl-xL-specific inhibitors, when combined with DNA-damaging agents or physical insults, trigger apoptosis in various cell types and C. elegans by releasing Bad and Bax from Bcl-xL.

bioRxiv · Jan 13, 2020Cancer Biology

The kinase inhibitor AT9283 selectively kills colorectal cancer cells with hyperactive NRF2

L. Torrente, G. Maan, L. Casares, A. Jackson, T. Honda, G. Wells, E. Kulesskiy, J. Saarela, A. T. Dinkova-Kostova, L. de la Vega

The paper identifies AT9283 as a drug that selectively kills colorectal cancer cells with hyperactive NRF2, showing its potential as a therapeutic target.

bioRxiv · Oct 21, 2019 · PreprintCancer Biology